Erratum: Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease (Blood (2015) 126:17 (2038-2046) DOI: 10.1182/blood-2015-02-629873);Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease

Blood

Volumn 126, Issue 17, 2015, Pages 2038-2046

  Gill, Joan C ^a,b   Castaman, Giancarlo ^c,d   Windyga, Jerzy ^e   Kouides, Peter ^f,g   Ragni, Margaret ^h,i   Leebeek, Frank W G ^j   Obermann Slupetzky, Ortrun ^k   Chapman, Miranda ^k   Fritsch, Sandor ^k   Pavlova, Borislava G ^k   Presch, Isabella ^k   Ewenstein, Bruce ^l  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c SAN BORTOLO HOSPITAL   (Italy)

^d Gastroenterology Unit Careggi   (Italy)

^e INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^f UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^g Mary M Gooley Hemophilia Center   (United States)

^h UNIVERSITY OF PITTSBURGH   (United States)

ⁱ Hemophilia Center of Western Pennsylvania   (United States)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k Technology GmbH   (Austria)

^l Baxalta US   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT VON WILLEBRAND FACTOR; RISTOCETIN; TRANEXAMIC ACID; HEMOSTATIC AGENT; RECOMBINANT PROTEIN; VON WILLEBRAND FACTOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSGEUSIA; ELIMINATION HALF-LIFE; EPISTAXIS; FEMALE; FIBRINOLYTIC THERAPY; GASTROINTESTINAL HEMORRHAGE; HEART RATE; HEMOSTASIS; HOT FLUSH; HUMAN; INFUSION RELATED REACTION; MALE; MEAN RESIDENCE TIME; MENORRHAGIA; ORAL BLEEDING; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; T WAVE INVERSION; TACHYCARDIA; THORAX PAIN; THROMBOSIS; VOLUME OF DISTRIBUTION AT STEADY-STATE; VON WILLEBRAND DISEASE; ADOLESCENT; AGED; BLOOD CLOTTING TEST; CLINICAL TRIAL; FOLLOW UP; HALF LIFE TIME; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TISSUE DISTRIBUTION; VON WILLEBRAND DISEASES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD COAGULATION TESTS; CROSS-OVER STUDIES; FEMALE; FOLLOW-UP STUDIES; HALF-LIFE; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84944904004     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/BLOOD.2020009144     Document Type: Erratum

References (38)

1. Hantgan RR, Hindriks G, Taylor RG, Sixma JJ, de Groot PG. Glycoprotein Ib, von Willebrand factor, and glycoprotein IIb: IIIa are all involved in platelet adhesion to fibrin in flowing whole blood. Blood. 1990;76(2):345-353.
2. Gill JC. Treatment of urgent bleeding in von Willebrand disease. Thromb Res. 2007;120(Suppl 1):S21-S25.
3. Huang RH, Wang Y, Roth R, et al. Assembly of Weibel-Palade body-like tubules from N-terminal domains of von Willebrand factor. Proc Natl Acad Sci USA. 2008;105(2):482-487.
4. Ginsburg D, Handin RI, Bonthron DT, et al. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science. 1985;228(4706):1401-1406.
5. Mancuso DJ, Tuley EA, Westfield LA, et al. Structure of the gene for human von Willebrand factor. J Biol Chem. 1989;264(33):19514-19527.
6. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987;69(2):454-459.
7. Sadler JE, Budde U, Eikenboom JC, et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103-2114.
8. Federici AB, Mazurier C, Berntorp E, et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood. 2004;103(6):2032-2038.
9. Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med. 2004;351(7):683-694.
10. Goudemand J, Scharrer I, Berntorp E, et al. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost. 2005;3(10):2219-2227.
11. Borel-Derlon A, Federici AB, Roussel-Robert V, et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost. 2007;5(6):1115-1124.
12. Favaloro EJ, Lloyd J, Rowell J, et al. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study. Thromb Haemost. 2007;97(6):922-930.
13. Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM; HAEMATE P Surgical Study Group. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost. 2007;5(7):1420-1430.
14. Soucie JM, De Staercke C, Monahan PE, et al; US Hemophilia Treatment Center Network. Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening. Transfusion. 2013;53(6):1217-1225.
15. Di Minno G, Canaro M, Ironside JW, et al. Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice. Haematologica. 2013;98(10):1495-1498.
16. Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virusinactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood. 1992;79(12):3130-3137.
17. Mannuccio PM, Lattuada A, Ruggeri ZM. Proteolysis of von Willebrand factor in therapeutic plasma concentrates. Blood. 1994;83(10):3018-3027.
18. Budde U, Metzner HJ, Müller HG. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease. Semin Thromb Hemost. 2006;32(6):626-635.
19. Lethagen S, Carlson M, Hillarp A. A comparative in vitro evaluation of six von Willebrand factor concentrates. Haemophilia. 2004;10(3):243-249.
20. Ofosu FA, Freedman J, Semple JW. Plasmaderived biological medicines used to promote haemostasis. Thromb Haemost. 2008;99(5):851-862.
21. Fischer BE. Recombinant von Willebrand factor: potential therapeutic use. J Thromb Thrombolysis. 1999;8(3):197-205.
22. Turecek PL, Schrenk G, Rottensteiner H, et al. Structure and function of a recombinant von Willebrand factor drug candidate. Semin Thromb Hemost. 2010;36(5):510-521.
23. Mannucci PM, Kempton C, Millar C, et al; rVWF Ad Hoc Study Group. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood. 2013;122(5):648-657.
24. Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA; Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost. 2002;87(2):224-230.
25. Mannucci PM, Chediak J, Hanna W, et al; Alphanate Study Group. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood. 2002;99(2):450-456.
26. Kasper CK. Laboratory tests for factor VIII inhibitors, their variation, significance and interpretation. Blood Coagul Fibrinolysis. 1991;2(Suppl 1):7-10.
27. Whelan SF, Hofbauer CJ, Horling FM, et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood. 2013;121(6):1039-1048.
28. Turecek PL, Mitterer A, Matthiessen HP, et al. Development of a plasma- and albuminfree recombinant von Willebrand factor. Hamostaseologie. 2009;29(Suppl 1):S32-S38.
29. Strandberg K, Lethagen S, Andersson K, Carlson M, Hillarp A. Evaluation of a rapid automated assay for analysis of von Willebrand ristocetin cofactor activity. Clin Appl Thromb Hemost. 2006;12(1):61-67.
30. Batlle J, López-Fernández MF, Fraga EL, Trillo AR, Pérez-Rodríguez MA. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease. Blood Coagul Fibrinolysis. 2009;20(2):89-100.
31. Kessler CM, Friedman K, Schwartz BA, Gill JC, Powell JS; Wilate PK Study Investigators. The pharmacokinetic diversity of two von Willebrand factor (VWF)/factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study. Thromb Haemost. 2011;106(2):279-288.
32. Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys. Blood Coagul Fibrinolysis. 2005;16(Suppl 1):S17-S21.
33. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424.
34. Reininger AJ. Function of von Willebrand factor in haemostasis and thrombosis. Haemophilia. 2008;14(Suppl 5):11-26.
35. Kragh T, Napoleone M, Fallah MA, Gritsch H, Schneider MF, Reininger AJ. High shear dependent von Willebrand factor self-assembly fostered by platelet interaction and controlled by ADAMTS13. Thromb Res. 2014;133(6):1079-1087.
36. Castaman G, Federici AB, Tosetto A, et al. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost. 2012;10(4):632-638.
37. Reininger AJ. The function of ultra-large von Willebrand factor multimers in high shear flow controlled by ADAMTS13. Hamostaseologie. 2015;35(3):225-233.
38. James PD, Lillicrap D, Mannucci PM. Alloantibodies in von Willebrand disease. Blood. 2013;122(5):636-640.